Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1972 1
1973 1
1975 2
1976 2
1978 1
1980 1
1983 2
1984 2
1985 1
1986 1
1987 2
1989 2
1990 4
1991 4
1992 2
1993 4
1994 4
1995 6
1996 3
1997 3
1998 4
1999 1
2000 3
2001 3
2002 7
2003 6
2004 9
2005 14
2006 9
2007 4
2008 10
2009 18
2010 14
2011 13
2012 21
2013 21
2014 20
2015 18
2016 29
2017 27
2018 35
2019 21
2020 37
2021 28
2022 31
2023 23
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

418 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Metastatic Oropharyngeal Carcinoma"
Page 1
Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment.
Marur S, Forastiere AA. Marur S, et al. Mayo Clin Proc. 2016 Mar;91(3):386-96. doi: 10.1016/j.mayocp.2015.12.017. Mayo Clin Proc. 2016. PMID: 26944243 Review.
Squamous cell carcinoma arises from multiple anatomic subsites in the head and neck region. ...For recurrent disease that is not amenable to a salvage local or regional approach and for metastatic disease, chemotherapy with or without a biological agent is indicated …
Squamous cell carcinoma arises from multiple anatomic subsites in the head and neck region. ...For recurrent disease that is not amen …
Palliative Radiation Therapy for Head and Neck Cancers.
Grewal AS, Jones J, Lin A. Grewal AS, et al. Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):254-266. doi: 10.1016/j.ijrobp.2019.05.024. Epub 2019 May 22. Int J Radiat Oncol Biol Phys. 2019. PMID: 31128145 Review.
An ideal palliative radiation regimen should alleviate symptoms secondary to the cancer with minimal treatment toxicity and side effects while improving a patient's quality of life. ...
An ideal palliative radiation regimen should alleviate symptoms secondary to the cancer with minimal treatment toxicity and side effe …
SEOM clinical guidelines for the treatment of head and neck cancer (2020).
Mesia R, Iglesias L, Lambea J, Martínez-Trufero J, Soria A, Taberna M, Trigo J, Chaves M, García-Castaño A, Cruz J. Mesia R, et al. Clin Transl Oncol. 2021 May;23(5):913-921. doi: 10.1007/s12094-020-02533-1. Epub 2021 Feb 26. Clin Transl Oncol. 2021. PMID: 33635468 Free PMC article.
Most relevant diagnostic and therapeutic changes from the last guideline have been updated: introduction of sentinel node biopsy in early oral/oropharyngeal cancer treated with surgery, concomitant radiotherapy with weekly cisplatin 40 mg/m(2) in the adjuvant setting, new …
Most relevant diagnostic and therapeutic changes from the last guideline have been updated: introduction of sentinel node biopsy in early or …
Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The ORATOR2 Phase 2 Randomized Clinical Trial.
Palma DA, Prisman E, Berthelet E, Tran E, Hamilton S, Wu J, Eskander A, Higgins K, Karam I, Poon I, Husain Z, Enepekides D, Hier M, Sultanem K, Richardson K, Mlynarek A, Johnson-Obaseki S, Odell M, Bayley A, Dowthwaite S, Jackson JE, Dzienis M, O'Neil J, Chandarana S, Banerjee R, Hart R, Chung J, Tenenholtz T, Krishnan S, Le H, Yoo J, Mendez A, Winquist E, Kuruvilla S, Stewart P, Warner A, Mitchell S, Chen J, Parker C, Wehrli B, Kwan K, Theurer J, Sathya J, Hammond JA, Read N, Venkatesan V, MacNeil SD, Fung K, Nichols AC. Palma DA, et al. JAMA Oncol. 2022 Jun 1;8(6):1-7. doi: 10.1001/jamaoncol.2022.0615. JAMA Oncol. 2022. PMID: 35482348 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: This international, multicenter, open-label parallel-group phase 2 randomized clinical trial was conducted at 9 tertiary academic cancer centers in Canada and Australia and enrolled patients with T1-T2N0-2 p16-positive OPSCC …
DESIGN, SETTING, AND PARTICIPANTS: This international, multicenter, open-label parallel-group phase 2 randomized clinical t …
Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis.
Mehanna H, Taberna M, von Buchwald C, Tous S, Brooks J, Mena M, Morey F, Grønhøj C, Rasmussen JH, Garset-Zamani M, Bruni L, Batis N, Brakenhoff RH, Leemans CR, Baatenburg de Jong RJ, Klussmann JP, Wuerdemann N, Wagner S, Dalianis T, Marklund L, Mirghani H, Schache A, James JA, Huang SH, O'Sullivan B, Nankivell P, Broglie MA, Hoffmann M, Quabius ES, Alemany L; HNCIG-EPIC group. Mehanna H, et al. Lancet Oncol. 2023 Mar;24(3):239-251. doi: 10.1016/S1470-2045(23)00013-X. Epub 2023 Feb 13. Lancet Oncol. 2023. PMID: 36796393 Free article.
BACKGROUND: p16(INK4a) (p16) immunohistochemistry is the most widely used biomarker assay for inferring HPV causation in oropharyngeal cancer in clinical and trial settings. However, discordance exists between p16 and HPV DNA or RNA status in some patients wi …
BACKGROUND: p16(INK4a) (p16) immunohistochemistry is the most widely used biomarker assay for inferring HPV causation in oropharyngeal …
Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.
Parmar A, Macluskey M, Mc Goldrick N, Conway DI, Glenny AM, Clarkson JE, Worthington HV, Chan KK. Parmar A, et al. Cochrane Database Syst Rev. 2021 Dec 20;12(12):CD006386. doi: 10.1002/14651858.CD006386.pub4. Cochrane Database Syst Rev. 2021. PMID: 34929047 Free PMC article. Review.
BACKGROUND: Oral cavity and oropharyngeal cancers are the most common cancers arising in the head and neck. ...We contacted trial authors for additional information or clarification when necessary. ...
BACKGROUND: Oral cavity and oropharyngeal cancers are the most common cancers arising in the head and neck. ...We contacted trial …
Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.
Jin BY, Campbell TE, Draper LM, Stevanović S, Weissbrich B, Yu Z, Restifo NP, Rosenberg SA, Trimble CL, Hinrichs CS. Jin BY, et al. JCI Insight. 2018 Apr 19;3(8):e99488. doi: 10.1172/jci.insight.99488. eCollection 2018 Apr 19. JCI Insight. 2018. PMID: 29669936 Free PMC article. Clinical Trial.
Human T cells transduced to express the TCR specifically recognized and killed HPV-16+ cervical and oropharyngeal cancer cell lines and mediated regression of established HPV-16+ human cervical cancer tumors in a mouse model. These findings support the therapeutic potentia …
Human T cells transduced to express the TCR specifically recognized and killed HPV-16+ cervical and oropharyngeal cancer cell lines a …
Human papillomavirus-related oropharyngeal carcinoma.
Saito Y, Homma A, Kiyota N, Tahara M, Hanai N, Asakage T, Matsuura K, Ota I, Yokota T, Sano D, Kodaira T, Motegi A, Yasuda K, Takahashi S, Tanaka K, Onoe T, Okano S, Imamura Y, Ariizumi Y, Hayashi R. Saito Y, et al. Jpn J Clin Oncol. 2022 Jul 8;52(7):700-706. doi: 10.1093/jjco/hyac049. Jpn J Clin Oncol. 2022. PMID: 35383359 Review.
It was not until around 2000 that human papillomavirus-related oropharyngeal carcinoma was recognized as carcinoma with clinical presentations different from nonrelated head and neck carcinoma. Twenty years after and with the revision of the tum …
It was not until around 2000 that human papillomavirus-related oropharyngeal carcinoma was recognized as carcinoma with …
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Sun XS, Tao Y, Le Tourneau C, Pointreau Y, Sire C, Kaminsky MC, Coutte A, Alfonsi M, Boisselier P, Martin L, Miroir J, Ramee JF, Delord JP, Clatot F, Rolland F, Villa J, Magne N, Elicin O, Gherga E, Nguyen F, Lafond C, Bera G, Calugaru V, Geoffrois L, Chauffert B, Zubel A, Zanna C, Brienza S, Crompton P, Rouits E, Gollmer K, Szyldergemajn S, Bourhis J. Sun XS, et al. Lancet Oncol. 2020 Sep;21(9):1173-1187. doi: 10.1016/S1470-2045(20)30327-2. Epub 2020 Aug 3. Lancet Oncol. 2020. PMID: 32758455 Clinical Trial.
We aimed to investigate the efficacy and safety of Debio 1143 in combination with standard chemoradiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck. METHODS: This double-blind, multicentre, randomised, phase 2 study …
We aimed to investigate the efficacy and safety of Debio 1143 in combination with standard chemoradiotherapy in patients with high-risk loca …
Machine Learning-Guided Adjuvant Treatment of Head and Neck Cancer.
Howard FM, Kochanny S, Koshy M, Spiotto M, Pearson AT. Howard FM, et al. JAMA Netw Open. 2020 Nov 2;3(11):e2025881. doi: 10.1001/jamanetworkopen.2020.25881. JAMA Netw Open. 2020. PMID: 33211108 Free PMC article.
OBJECTIVE: To evaluate whether machine learning models could identify patients with intermediate-risk head and neck squamous cell carcinoma who would benefit from chemoradiation. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included patients diagnosed with squamous …
OBJECTIVE: To evaluate whether machine learning models could identify patients with intermediate-risk head and neck squamous cell carcino …
418 results